UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation

Although MDM2 is known to be a critical negative regulator of p53, MDM2 only catalyzes p53 mono-or multiple mono-ubiquitination in vitro and in vivo, which is insufficient for the initiation of proteasomal degradation. MDM2 does not polyubiquitinate p53 in vitro, however, which indicates that the activity of other ubiquitin ligase(s) or cofactor(s) is required for MDM2-mediated p53 polyubiquitination and degradation. In our recent study, we demonstrated that UBE4B, an E3 and E4 ubiquitin ligase with a U-box domain, interacts physically with both p53 and MDM2. Our findings revealed that UBE4B negatively regulates the level of p53, and inhibits p53-dependent transactivation and apoptosis. We propose that inhibition of MDM2 binds to UBE4B, which may provide another approach to inhibit MDM2 E3 ligase activity for tumor suppressor p53. It could lead to novel anti-cancer therapies with the possibility to reduce the public health burden from cancer.